Earnings call Tonix Pharmaceuticals delivered a strong Q2 2026, with Tonmya net sales reaching $11M (197% QoQ growth), driven by robust prescription and refill trends. Management reaffirmed broadening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results